Evidence map›Paper›PMID 40394010›Full record

ArticleNature communications2025

Switchable organocatalytic enantioselective sulfenocyclization of cyclohexadienes enabling chemodivergent access to chiral bicyclo[m.n.1] ring systems.

Bing-Qian Zhang, Lei Chen, Wen-Ying Xiao, Yidong Liu, Yin-Long Li, Jun Deng

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bing-Qian Zhang *Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.
Lei Chen *Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.
Wen-Ying XiaoChongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.
Yidong LiuChongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China. yidong@cqu.edu.cn.ORCID http://orcid.org/0000-0002-7988-8908
Yin-Long LiDepartment of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, GA, USA. yinlong.li@emory.edu.ORCID http://orcid.org/0000-0002-8864-1712
Jun DengChongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China. jdeng@cqu.edu.cn.ORCID http://orcid.org/0000-0002-6547-0244

Funding

National Natural Science Foundation of China (National Science Foundation of China) 21871034National Natural Science Foundation of China (National Science Foundation of China) 22301025
6 · The paper itself

Abstract

The precise control over regio- and stereoselectivity from the same substrate represents a significant challenge in organic chemistry. Herein, a switchable organocatalytic enantioselective carbosulfenylation/sulfenolactonization of cyclohexa-1,4-dienes to access the chiral bicyclo[m.n.1] ring systems, which are the critical core skeleton of many important natural products and biologically active compounds, is achieved. By simply tuning the substituent of the sulfenylating agent, a series of synthetically challenging chiral bridged bicyclo[3.3.1]nonanes and 2-oxabicyclo[3.2.1]octanes bearing three consecutive stereocenters are obtained with good yields and excellent enantioselectivities (up to 94% yield and 97% ee). Furthermore, the initial investigation of the bicyclic derivative as a chiral ligand in metal catalysis is also conducted. Our findings offer a version of switchable divergent asymmetric synthesis in which different products can be controllably generated from an identical set of substrates by simply adjusting reaction parameters.

Identifiers

PMID40394010
PMCPMC12092718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.